This early phase I trial studies how well the use of a continuous positive airway pressure
(CPAP) machine works in treating obstructive sleep apnea in patients with polycythemia vera
or essential thrombocythemia. Obstructive sleep apnea is a condition where a person stops
breathing during sleep, and is estimated to affect 30 to 50 percent of patients with
polycythemia vera or essential thrombocythemia. A patient with obstructive sleep apnea
typically snores, has disrupted sleep, experiences morning headaches, and has daytime
sleepiness. Patients diagnosed with obstructive sleep apnea are typically treated with a
device called CPAP. The CPAP provides pressurized air that keeps upper air passages open
during sleep and may prevent them from narrowing or collapsing as occurs during snoring or
I. To understand effects of continuous positive airway pressure (CPAP) for obstructive sleep
apnea (OSA) on the course of polycythemia vera/essential thrombocythemia (PV/ET).
I. To estimate prevalence of OSA in patients with myeloproliferative neoplasms. II. To
understand effects of CPAP for sleep apnea on the course of myeloproliferative neoplasms
III. To correlate OSA severity with thrombotic and inflammatory marker values in patients
with PV/ET at baseline.
OUTLINE: Patients are assigned to 1 of 2 cohorts.
COHORT I (OBSERVATIONAL COHORT): Patients not diagnosed with OSA undergo observation for 6
COHORT II (TREATMENT COHORT): Patients diagnosed with OSA and prescribed a CPAP machine for
treatment receive continuous treatment with CPAP for 6 months.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.